Collegium Pharmaceutical (NASDAQ:COLL) Stock Moved Down to “Hold” by Wall Street Zen

Wall Street Zen cut shares of Collegium Pharmaceutical (NASDAQ:COLL – Free Report) from a buy rating to a hold rating in a research note published on Sunday,Wall Street Zen reports.

Several other brokerages also recently weighed in on COLL. Needham & Company LLC dropped their target price on shares of Collegium Pharmaceutical from $46.00 to $44.00 and set a “buy” rating for the company in a report on Thursday, November 5th. Zacks Research upgraded shares of Collegium Pharmaceutical from a “strong sell” rating to a “strong-buy” rating in a report on Thursday, October 15th. Barclays dropped their price objective on shares of Collegium Pharmaceutical from $56.00 to $48.00 and set an “overweight” rating for the company in a report on Wednesday, August 19th. Leerink Partners initiated coverage on Collegium Pharmaceutical in a research report on Wednesday, September 9th. They set an “outperform” rating and a $45.00 price objective for the company. Finally, Piper Sandler reduced their target price on Collegium Pharmaceutical from $43.00 to $28.00 and set a “neutral” rating on the stock in a report on Friday, November 6th. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $44.88.

Read Our Latest Stock Analysis on COLL

Collegium Pharmaceutical Price Performance

NASDAQ COLL opened at $25.32 on Friday. The company has a 50-day moving average price of $23.04 and a 200-day moving average price of $32.26. The company has a quick ratio of 0.87, a current ratio of 1.01 and a debt-to-equity ratio of 3.44. The firm has a market capitalization of $786.95 million, a P/E ratio of 25.32, a PEG ratio of 0.79 and a beta of 0.74. Collegium Pharmaceutical has a 52 week low of $21.43 and a 52 week high of $50.79.

Collegium Pharmaceutical (NASDAQ:COLL – Get Free Report) last released its quarterly earnings results on Thursday, November 5th. The specialty pharmaceutical company reported $1.96 earnings per share for the quarter, topping the consensus estimate of $1.86 by $0.10. The business had revenue of $216.34 million for the quarter, compared to the consensus estimate of $216.03 million. Collegium Pharmaceutical had a net margin of 4.68% and a return on equity of 85.14%. The company’s quarterly revenue was up 67.4% on a year-over-year basis. During the same period last year, the firm earned $2.25 earnings per share. Equities research analysts anticipate that Collegium Pharmaceutical will post 6.42 earnings per share for the current year.

Institutional Investors Weigh In On Collegium Pharmaceutical

Several large investors have recently added to or reduced their stakes in the stock. Mirae Asset Global Investments Co. Ltd. purchased a new position in shares of Collegium Pharmaceutical in the 3rd quarter worth approximately $36,000. Global Retirement Partners LLC increased its position in shares of Collegium Pharmaceutical by 530.3% during the 3rd quarter. Global Retirement Partners LLC now owns 2,017 shares of the specialty pharmaceutical company’s stock valued at $44,000 after purchasing an additional 1,697 shares during the last quarter. PNC Financial Services Group Inc. increased its position in shares of Collegium Pharmaceutical by 42.2% during the 1st quarter. PNC Financial Services Group Inc. now owns 1,408 shares of the specialty pharmaceutical company’s stock valued at $47,000 after purchasing an additional 418 shares during the last quarter. Assetmark Inc. lifted its position in Collegium Pharmaceutical by 9.3% in the first quarter. Assetmark Inc. now owns 3,923 shares of the specialty pharmaceutical company’s stock worth $130,000 after buying an additional 335 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. lifted its position in Collegium Pharmaceutical by 15.1% in the third quarter. China Universal Asset Management Co. Ltd. now owns 5,940 shares of the specialty pharmaceutical company’s stock worth $132,000 after buying an additional 778 shares during the last quarter.

Collegium Pharmaceutical Company Profile

(Get Free Report)

Collegium Pharmaceutical is a U.S.-based specialty pharmaceutical company focused on developing and commercializing medicines for pain management. Its portfolio includes Xtampza ER, an extended-release oxycodone product; Belbuca, a buprenorphine buccal film for chronic pain; and Nucynta, tapentadol tablets available in immediate- and extended-release formulations. The company also markets Symproic, a treatment for opioid-induced constipation. Collegium’s products include extended-release and opioid medicines, and the company emphasizes responsible use and risk-mitigation measures in its commercial activities.

Featured Articles

Analyst Recommendations for Collegium Pharmaceutical (NASDAQ:COLL)

Receive News & Ratings for Collegium Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.